Biomedical Policy · us
FDA Establishes Biologics Safety Council to Strengthen Postmarketing Oversight of Vaccines and Gene Therapies
The new council will operate independently of the product offices responsible for premarket review and report directly to the CBER director, evaluating safety signals and recommending labeling changes, additional risk management measures and, when necessary, market withdrawal.
After a vaccine or gene therapy is approved for marketing, safety assessments must continue to be updated as experience with its use grows. On November 19, the U.S. Food and Drug Administration (FDA) announced the establishment of the Center for Biologics Evaluation and Research Safety Council (CBER Safety Council, CSC), creating a dedicated mechanism to review risks that emerge after marketing. Its scope covers vaccines, cell and gene therapies, and blood and blood products regulated by the center.
The core of this change is to establish a clear line of accountability for postmarketing safety assessments. The regulatory affairs professional organization RAPS reported on November 20 that the new council evolved from CBER’s existing safety working group. It will operate separately from the product offices and report directly to the center director, with a dedicated cross-functional team responsible for oversight.
According to the FDA announcement, the council will review postmarketing safety signals, conduct benefit-risk assessments and submit regulatory recommendations to CBER leadership. Potential measures include changes to safety labeling, requirements for Risk Evaluation and Mitigation Strategies (REMS), additional safety-related postmarketing study requirements, and market withdrawal for safety reasons. The council is responsible for making recommendations, while responsibility for taking appropriate regulatory action remains with the center director.
This arrangement will also draw on existing monitoring resources. The council will be managed by the senior advisor for postmarketing safety and bring together CBER’s pharmacovigilance and analytics teams. The FDA also listed the Sentinel System, the Vaccine Adverse Event Reporting System (VAERS), and the U.S. Centers for Disease Control and Prevention’s Vaccine Safety Datalink as part of its formal monitoring collaboration network.
For patients and healthcare professionals, a key issue is how risk determinations are communicated. The FDA said that after making major safety determinations, the council will promptly release public safety information explaining the evidence underlying its decisions. Members of the public and healthcare professionals can continue to report safety concerns through existing channels such as VAERS and MedWatch.
The new council took effect on November 19, but the FDA said further information on its organizational structure, membership and operating procedures would be announced separately. What can currently be confirmed is a change to the oversight structure and advisory responsibilities; whether this arrangement can shorten the time needed to assess safety signals and improve consistency in decision-making remains to be tested in practice.